H
Hendrik Rathke
Researcher at University Hospital Heidelberg
Publications - 40
Citations - 2263
Hendrik Rathke is an academic researcher from University Hospital Heidelberg. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 14, co-authored 28 publications receiving 1167 citations.
Papers
More filters
Journal ArticleDOI
68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Clemens Kratochwil,Paul Flechsig,Thomas Lindner,Labidi Abderrahim,Annette Altmann,Annette Altmann,Walter Mier,Sebastian Adeberg,Hendrik Rathke,Manuel Röhrich,Hauke Winter,Peter K. Plinkert,Frederik Marmé,Matthias Lang,Hans-Ulrich Kauczor,Dirk Jäger,Dirk Jäger,Jürgen Debus,Jürgen Debus,Uwe Haberkorn,Uwe Haberkorn,Frederik L. Giesel +21 more
TL;DR: The high and rather selective tumor uptake on 68Ga-FAPI PET/CT may open up new applications for noninvasive tumor characterization, staging examinations, or radioligand therapy.
Journal ArticleDOI
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding.
Clemens Kratochwil,Frank Bruchertseifer,Hendrik Rathke,Marcus Bronzel,Christos Apostolidis,Wilko Weichert,Uwe Haberkorn,Uwe Haberkorn,Frederick Lars Giesel,Alfred Morgenstern +9 more
TL;DR: For advanced-stage patients, a treatment activity of 100 kBq/kg of 225Ac-PSMA-617 per cycle repeated every 8 wk presents a reasonable trade-off between toxicity and biochemical response.
Journal ArticleDOI
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
Clemens Kratochwil,Frank Bruchertseifer,Hendrik Rathke,Markus Hohenfellner,Frederik L. Giesel,Uwe Haberkorn,Uwe Haberkorn,Alfred Morgenstern +7 more
TL;DR: A positive response for surrogate parameters demonstrates remarkable antitumor activity for 225Ac-PSMA-617 in a retrospectively analyzed group of patients, indicating a promising duration of tumor control, especially considering the unfavorable prognostic profile of the selected advanced-stage patients.
Journal ArticleDOI
Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas.
Manuel Röhrich,Patrick Naumann,Frederik L. Giesel,Peter L. Choyke,Fabian Staudinger,Annika K. Wefers,Dawn P Liew,Clemens Kratochwil,Hendrik Rathke,Jakob Liermann,Klaus Herfarth,Dirk Jäger,Jürgen Debus,Uwe Haberkorn,Matthias Lang,Stefan A. Koerber +15 more
TL;DR: 68Ga-FAPI PET/CT led to restaging in half of the patients with PDAC and most patients with recurrent disease compared with standard of care imaging, and the clinical value of 68Ga- FAPIPET/CT should be further investigated.
Journal ArticleDOI
Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617.
Clemens Kratochwil,Karl Schmidt,Ali Afshar-Oromieh,Frank Bruchertseifer,Hendrik Rathke,Alfred Morgenstern,Uwe Haberkorn,Uwe Haberkorn,Frederik L. Giesel +8 more
TL;DR: Dosimetry of 213Bi-PSMA-617 is in a range traditionally considered reasonable for clinical application, Nevertheless, it suffers from higher perfusion-dependent off-target radiation and a longer biological half-life of PSma-617 in dose-limiting organs than the physical half- life of 213 bi, rendering this nuclide as a second choice radiolabel for targeted alpha therapy of prostate cancer.